- Home
- ZYME vs DFIN Comparison
ZYME vs DFIN Comparison
Compare ZYME & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- DFIN
- Stock Information
- Founded
- ZYME 2003
- DFIN 1983
- Country
- ZYME United States
- DFIN United States
- Employees
- ZYME N/A
- DFIN N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- DFIN Other Consumer Services
- Sector
- ZYME Health Care
- DFIN Consumer Discretionary
- Exchange
- ZYME Nasdaq
- DFIN Nasdaq
- Market Cap
- ZYME 1.2B
- DFIN 1.4B
- IPO Year
- ZYME 2017
- DFIN N/A
- Fundamental
- Price
- ZYME $16.46
- DFIN $45.36
- Analyst Decision
- ZYME Strong Buy
- DFIN Strong Buy
- Analyst Count
- ZYME 7
- DFIN 3
- Target Price
- ZYME $22.00
- DFIN $65.67
- AVG Volume (30 Days)
- ZYME 889.7K
- DFIN 362.8K
- Earning Date
- ZYME 11-06-2025
- DFIN 10-29-2025
- Dividend Yield
- ZYME N/A
- DFIN N/A
- EPS Growth
- ZYME N/A
- DFIN N/A
- EPS
- ZYME N/A
- DFIN 1.12
- Revenue
- ZYME $134,481,000.00
- DFIN $750,800,000.00
- Revenue This Year
- ZYME $99.52
- DFIN N/A
- Revenue Next Year
- ZYME N/A
- DFIN $4.66
- P/E Ratio
- ZYME N/A
- DFIN $40.62
- Revenue Growth
- ZYME 116.21
- DFIN N/A
- 52 Week Low
- ZYME $9.03
- DFIN $37.80
- 52 Week High
- ZYME $19.98
- DFIN $69.93
- Technical
- Relative Strength Index (RSI)
- ZYME 36.30
- DFIN 35.92
- Support Level
- ZYME $17.27
- DFIN $44.20
- Resistance Level
- ZYME $19.98
- DFIN $46.86
- Average True Range (ATR)
- ZYME 0.76
- DFIN 1.99
- MACD
- ZYME -0.27
- DFIN -0.47
- Stochastic Oscillator
- ZYME 11.48
- DFIN 11.15
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.